Company Details Total Shares Out Standing (millions): 20 Market Capitalization ($ millions): $37 Institutional Ownership: 42.8% Price (as of 9/30/2011) 1.9
Ownership Analysis # Of Holders Shares Total Shares Held: 9 8,359,549 New Positions: 2 20,645 Increased Positions: 4 770,157 Decreased Positions: 2 25,757 Holders With Activity: 6 795,914 Sold Out Positions: 0 0 Click on the column header links to resort ascending (ar_bk_up.gif (64 bytes)) or descending (ar_bk_dn.gif (64 bytes)).
Owner Name Select a name below for more information. Date Shares Held Change (Shares) % Change (Shares) Value ($1000) LANSDOWNE PARTNERS L... 6/30/2011 3,905,676 247,000 6.75% $7,421 MARXE AUSTIN W & GRE... 6/30/2011 3,324,424 (25,750) (0.77%) $6,316 PERCEPTIVE ADVISORS ... 6/30/2011 907,512 502,512 124.08% $1,724 GEDULD E E 6/30/2011 94,300 0 0.00% $179 FIRST MANHATTAN CO 6/30/2011 90,496 0 0.00% $172
para, others yes to several questions...it could be the BoD is shopping the co. LT but interim CEO Mc Narin must be replaced now, that will be a must, and I too think the founder KD had many loyalists and turnover sometimes like this portends BIG internal changes coming.
I always felt CM was brought in to RUN THE SHIP inside w/ all this change--you know what I mean keep up the momo w/ the sales force, all the internals in the lab, new layers of ability, smooth the transition...
...if U think U R next to be ousted you just put out feelers and jump ship on your terms rather that wait for the pink slip..in this business thats very prominent...NO real loyalty in Dx these days!
That being said, all the fundamentals seem in place to me, and CM is very experienced w/ Roche Dx background btw, and like U say they are adding new tests...Melanoma w/ Ipi(BMY) approved now is I think rather important...
<New ResponseDX(TM) Test Panel Launched - In June 2011, Response Genetics announced the nation-wide availability of its newest test panel, ResponseDX: Melanoma(TM), a proprietary, PCR-based diagnostic test that quantitatively analyzes mutations in the BRAF gene - a key component in cell signaling and growth. Such information can help physicians make treatment decisions for patients with this aggressive form of skin cancer. >
...so Reps had this new Melanoma test in the bag for all of Q-3 and what it contributes is any ones guess? I must say Melanoma is quite prevalent on the west coast w/ all the surfing so it could be a real +, I only know that when I called on docs, when I had something NEW and Important they said, ""Come in lets talk!""
This test is a door opener imo!
...access is key in any business!
...the UNCERTAINTY of all these changes is creating investor risk, and so I try to buy down here...its just that plain and simple to me para...